Burosumab is a fibroblast growth factor 23 blocking antibody used to treat X-linked hypophosphatemia. The U.S. Food and Drug Administration approved Crysvita (burosumab) in April 2018.
- Mechanism
- Curator reviewed · 2 references
Burosumab is a recombinant human monoclonal antibody (IgG1) that both binds to and inhibits the actions of fibroblast growth factor 23 (FGF23). By inhibiting this growth factor, burosumab increases the tubular reabsorption of phosphate from the kidney and thus increases serum concentration of 1, 25 dihydroxy-Vitamin D. This form of vitamin D enhances intestinal absorption of phosphate and calcium, supporting bone mineralization.
- Primary indication
- This drug is indicated for the treatment of X-linked hypophosphatemia with radiological evidence of bone disease in children of 1 year of age and older and adolescents with growing skeletons.Curator reviewed · 2 structured indications
- Formula / weight
- C6388H9904N1700O2006S46 · 144100.0 Da
- First approval
- Canada, 2022 · United States, 2018 · European Union, 2021
- Also known as
- Burosumab (genetical recombination) · burosumab-twza
- Code names
- KRN-23
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Burosumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account